HF
SLN

HRT Financial’s Silence Therapeutics SLN Stock Holding History

HRT Financial’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63K Buy
+11,994
New +$66K ﹤0.01% 3423
2025
Q4 		– Sell
-10,887
Closed -$56K – 3960
2025
Q3 		$56K Buy
+10,887
New +$60.5K ﹤0.01% 2591

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

HRT Financial's SLN Position: Q1 2026 in Review

HRT Financial opened a new position in Silence Therapeutics (SLN) in Q1 2026: 11,994 shares worth $63K. The stake represents ﹤0.01% of the portfolio and ranks #3423 among its holdings. This is a return to the name: HRT Financial previously reported a position in SLN as recently as Q3 2025.

HRT Financial first reported a position in SLN in Q3 2025 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • HRT Financial held 11,994 shares of Silence Therapeutics worth $63K as of Q1 2026.
  • Silence Therapeutics was a new HRT Financial position in Q1 2026.
  • Silence Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3423 holding.
  • HRT Financial first reported a position in Silence Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.